Drug Trial Radar · NCT05011669
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Apr 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Aug 16, 2021
Primary completion
Apr 16, 2023
Study completion Jun 16, 2023
Sponsor
- Lead sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of Lurasidone initiated with 40mg and 80mg in treatment with acute phase patients with schizophrenia
Conditions
- Schizophrenia
Interventions
LurasidoneDrug
Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of discontinuation due to adverse eventsTime frame: during the 6 weeks of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Sixth Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.